secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109714
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences reports Q3 2025 results; Phase 1b AD trial over 85% enrolled
--------------------------------------------------------------------------------

- Cash $15.4M at Sep 30, 2025, up from $13.3M at Dec 31, 2024; raised ~$21.6M in July 2025.
- Phase 1b PRECISE-AD trial over 85% enrolled; Cohorts 1 and 2 fully enrolled.
- DSMB unanimously recommended proceeding to third dose cohort; interim data Q2 2026, top-line Q4 2026.
- Operating loss $11.8M for Q3 2025 vs $4.4M in Q3 2024, driven by increased R&D on PMN310 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/0001104659-25-109714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer